report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
University of California at San Francisco, USA.
The clinical and radiologic impact of natalizumab (Tysabri) as therapy for multiple sclerosis (MS) is assessed. On the basis of Class I evidence, natalizumab has been demonstrated to reduce measures of disease activity and to improve measures of disease severity in patients with relapsing-remitting (RR) MS (Level A). The relative efficacy of natalizumab compared to current disease-modifying therapies cannot be defined accurately (Level U). Similarly, the value of natalizumab in the treatment of secondary progressive (SP) MS is unknown (Level U).
PMID: 18765653 [PubMed - in process]
CLICK HERE FOR FULL ABSTRACT & RELATED INFORMATION